Kintsugi Therapeutics — Seed · approximately €986K

Kintsugi Therapeutics is a biopharma company developing KIN102 for non-alcoholic steatohepatitis (NASH). It raised about €986K (El Referente rounds it to €1M) from local investors in under a week through the equity crowdfunding platform Capital Cell. The company had raised €691K before this and planned a €3.5M Series A in late 2022.